Compare FSBW & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | KALA |
|---|---|---|
| Founded | 1936 | 2009 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.4M | 319.6M |
| IPO Year | 2011 | 2017 |
| Metric | FSBW | KALA |
|---|---|---|
| Price | $40.80 | $0.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $46.00 | $31.50 |
| AVG Volume (30 Days) | 8.1K | ★ 2.9M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | ★ 41.50 |
| EPS | ★ 4.29 | N/A |
| Revenue | ★ $4,612,000.00 | N/A |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $9.52 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $36.72 | $0.15 |
| 52 Week High | $44.22 | $20.58 |
| Indicator | FSBW | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 44.73 |
| Support Level | $39.44 | $0.15 |
| Resistance Level | $40.67 | $0.72 |
| Average True Range (ATR) | 1.16 | 0.02 |
| MACD | 0.30 | 0.01 |
| Stochastic Oscillator | 76.21 | 78.47 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.